17,261 trials
Solid Tumors · Relapsed/Refractory Sarcomas
Primary: To Establish the Dose Limiting Toxicity (DLT)
Postoperative Pain
Primary: Change in Vaginal Pain Scores Using the Defense and Veterans Pain Rating Scale (Visual Analog Scale) Between Bupivacaine Alone Versus Exparel® Following Posterior…
Surgical Recovery
Primary: NFkB Signaling in Innate Immune Cells — 0.68; 0.69; 0.71; 0.71 NFkB (p65) arcsinh ratio
Attention Deficit Disorder · Attention Deficit Hyperactivity Disorder
Primary: Change in Score on Barkley Adult ADHD Rating Scale-IV (BAARS-IV) — 23.27; 23.1 score on a scale
Cutaneous Melanoma · Melanoma · Melanoma of Unknown Primary
Primary: Immune T-cell Response to NY-ESO-1 — 15; 10 Participants
COVID-19
Primary: Percentage of Participants Who Experience COVID-19 Related Hospitalization or Death From Any Cause — 0.9; 0.9; 0.9 Percentage of participants
Small Fiber Neuropathy
Primary: Change in Weekly Average of Daily Pain Intensity on the 11 Point NRS — -2.018; -0.933 units on a scale — p=<0.0001
Non-alcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Adverse Events — 42; 41; 40; 42 Participants
Cocaine Dependence
Primary: Cocaine Use by Self-report — 67; 67 Percent of cocaine-free (abstinent)days — p=0.972
Attention Deficit Disorder With Hyperactivity
Primary: Change From Baseline in Total Attention-Deficit Hyperactivity Disorder Rating Scale IV (ADHD-RS-IV) Score — -16.2; -7.9 score on a scale — p=<0.001
Breast Cancer
Primary: Adiponectin — 1308 pg/ml
Incurable Platinum Refractory Germ Cell Tumors · Tumors
Primary: Recommended Phase 2 Dose (RP2D) of ASP1650 — 1500 Milligram per meter square (mg/m^2)
Cytomegalovirus (CMV) Infections
Primary: Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)…
Gout Chronic
Primary: Proportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks — 19; 4; 3; 6 Participants — p=<0.01
Acne Vulgaris
Primary: Inflammatory Lesion Counts — -29.9; -26.7; -24.8; -26.8 lesions